Boundless Bio will present research on cancer therapies at the AACR-NCI-EORTC conference in Boston, October 23, 2025.
Quiver AI Summary
Boundless Bio, a clinical-stage oncology company focused on transformative therapies for oncogene amplified cancers, announced a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, MA. The poster will discuss the synergistic effects of combining two selective inhibitors, BBI-825 and BBI-355, targeting unique dependencies of these cancers. Boundless Bio's research centers on extrachromosomal DNA (ecDNA) as a cause of oncogene amplification and includes their phase 1/2 POTENTIATE clinical trial evaluating these compounds. The company is also developing another ecDNA-directed therapeutic candidate, BBI-940. Boundless Bio is based in San Diego, CA.
Potential Positives
- Announcement of a poster presentation at a prestigious cancer conference enhances the company's visibility and credibility within the oncology community.
- Presentation of new combination therapy targeting oncogene amplified cancers demonstrates the company's commitment to innovative solutions for unmet medical needs.
- Highlighting ongoing clinical trials for ecDNA-directed therapeutic candidates signals progress in the development pipeline, potentially increasing investor confidence.
Potential Negatives
- Limited current clinical data is presented, which may raise concerns about the efficacy and safety of their therapies in development.
- The announcement highlights a phase 1/2 clinical trial, suggesting that the company is still in early stages of testing, which may imply a longer timeline before potential commercialization.
- Focus on a niche market (oncogene amplified cancers) could limit the company's broader appeal and market potential.
FAQ
What is Boundless Bio's focus in oncology?
Boundless Bio focuses on developing therapies targeting extrachromosomal DNA (ecDNA) to address oncogene amplified cancers.
When is Boundless Bio presenting at the AACR-NCI-EORTC conference?
The presentation is scheduled for October 23, 2025, from 12:30 to 4:00 PM ET.
What is the title of the presentation at the conference?
The title is "Synergistic oral combination of selective RNR inhibitor BBI-825 with selective CHK1 inhibitor BBI-355."
Where is Boundless Bio headquartered?
Boundless Bio is headquartered in San Diego, California.
What are the key drug candidates being developed by Boundless Bio?
The key candidates include BBI-355, BBI-825, and BBI-940, targeting ecDNA-related cancers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BOLD Hedge Fund Activity
We have seen 18 institutional investors add shares of $BOLD stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NUVEEN, LLC removed 3,958,413 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,997,997
- RA CAPITAL MANAGEMENT, L.P. removed 2,180,631 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,202,437
- BLACKROCK, INC. removed 563,939 shares (-89.8%) from their portfolio in Q2 2025, for an estimated $569,578
- BOXER CAPITAL MANAGEMENT, LLC removed 250,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $252,500
- PFM HEALTH SCIENCES, LP removed 240,513 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $242,918
- MILLENNIUM MANAGEMENT LLC added 213,561 shares (+inf%) to their portfolio in Q2 2025, for an estimated $215,696
- RBF CAPITAL, LLC added 200,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $202,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BOLD Analyst Ratings
Wall Street analysts have issued reports on $BOLD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/11/2025
To track analyst ratings and price targets for $BOLD, check out Quiver Quantitative's $BOLD forecast page.
$BOLD Price Targets
Multiple analysts have issued price targets for $BOLD recently. We have seen 3 analysts offer price targets for $BOLD in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $4.0 on 08/11/2025
- Michael Cherny from Leerink Partners set a target price of $3.0 on 05/28/2025
Full Release
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Boundless Bio , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA.
Details of the presentations are as follows:
Title:
Synergistic oral combination of selective RNR inhibitor BBI-825 with selective CHK1 inhibitor BBI-355 targets unique dependencies of oncogene amplified cancers
Abstract Number:
LB-A022
Session:
Poster Session A
Session Date and Time:
Thursday October 23, 2025, 12:30-4:00 PM ET
Location:
Level 2, Exhibit Hall D
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidates (ecDTx), BBI-355, an oral, selective inhibitor of checkpoint kinase 1 (CHK1), and BBI-825, an oral, selective inhibitor of ribonucleotide reductase (RNR). These compounds are being evaluated in combination in patients with oncogene amplified cancers in the Company’s phase 1/2 POTENTIATE clinical trial. Boundless Bio is conducting IND-enabling studies of another ecDTx, BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader. Boundless Bio is headquartered in San Diego, CA.
For more information, visit www.boundlessbio.com and follow us on LinkedIn and X .
Investor Contacts:
James Lee, Boundless Bio, Inc.
[email protected]
Renee Leck, THRUST Strategic Communications
[email protected]
Media Contact:
Carly Scaduto
[email protected]
